measles and rubella vaccine / Generic mfg. - LARVOL DELTA

A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants (clinicaltrials.gov) - P2 | N=183 | Completed | Sponsor: GlaxoSmithKline | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease

Measles in Ugandan Children Under 18 Months of Age: A Retrospective Study of Case-based Surveillance, 2018-2024. (PubMed, Open Forum Infect Dis) - "Infants nine to 18 months old comprise most of the measles cases (59.0%; 777/1316). To achieve better control of measles transmission, review of the current vaccination policies with strengthened vaccination and surveillance systems are recommended."

Journal • Retrospective data • Infectious Disease • Measles • Rubella

Preliminary safety data from a randomised trial of early versus standard timing of administration of measles-rubella vaccine in Ugandan infants. (PubMed, Discov Med (Singap)) - P2 | "We provide further evidence on the safety of administering a measles-containing vaccine at six months of age.Trial registration: The trial was registered on 31st October 2024 with Clinicaltrials.gov with the identifier NCT06667206. The online version contains supplementary material available at 10.1007/s44337-026-00649-x."

Clinical • Journal • Human Immunodeficiency Virus • Infectious Disease • Measles • Rubella

MEASLES-RUBELLA VACCINE AT 6 OR 9 MONTHS OF AGE IN UGANDAN INFANTS: PRELIMINARY DATA FROM A RANDOMISED CONTROLLED TRIAL (ESPID 2026) - "An earlier start to current measles vaccination programs may provide earlier protection, but concerns exist that measles vaccines will be less protective at earlier ages. The high number of measles cases identified during the trial thus far indicates substantial ongoing community transmission. Immunological analyses are underway, and an efficacy trial extension is planned."

Clinical • Infectious Disease • Measles • Rubella

A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants (clinicaltrials.gov) - P2 | N=215 | Active, not recruiting | Sponsor: GlaxoSmithKline | Recruiting ➔ Active, not recruiting | N=516 ➔ 215 | Trial completion date: Apr 2026 ➔ Sep 2026 | Trial primary completion date: Apr 2026 ➔ Sep 2026

Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Infectious Disease

SHIELD: Strengthening HPV Immunization Through EPI Leveraged Delivery (clinicaltrials.gov) - P2 | N=115 | Recruiting | Sponsor: International Vaccine Institute | Not yet recruiting ➔ Recruiting | Initiation date: Jan 2026 ➔ Apr 2026

Enrollment open • Trial initiation date • Oncology

Infant Malaria Vaccine Schedule Optimization (clinicaltrials.gov) - P2 | N=964 | Recruiting | Sponsor: PATH | Trial completion date: Mar 2028 ➔ Sep 2027 | Trial primary completion date: Mar 2028 ➔ Sep 2027

Trial completion date • Trial primary completion date • Infectious Disease • Malaria

ESTIMATING THE COSTS AND BUDGET IMPACT OF STRATEGIES TO SUSTAINING PNEUMOCOCCAL CONJUGATE VACCINE AFTER GAVI SUPPORT GRADUATION IN LAO PDR (ISPPD 2026) - "The 1+1 schedule included one primary dose at 14 weeks and booster co-administered with measles-rubella vaccine at 9 months, using PCV10 at US$2.00 per dose.Results Transitioning to a 1+1 schedule would reduce total program doses by 39%, from 2,716,153 to 1,666,467 doses over five years. Annual savings in the base case would range from US$344,767 in 2026 to US$462,711 in 2030.Conclusions Transitioning to 1+1 PCV schedule represents a financially viable strategy for sustaining pneumococcal vaccination in Lao PDR post-Gavi transition. The substantial cost savings provide evidence-based options for maintaining vaccine program continuity within constrained budgets while preserving immunization program effectiveness."

HEOR • Infectious Disease • Measles • Pneumococcal Infections • Rubella

Utilizing administrative data to enhance the Health Management Support Program for public assistance recipients aged <40 years: Lessons from Toyonaka City (PubMed, Nihon Koshu Eisei Zasshi) - "Descriptive analyses were conducted using the integrated dataset.Results　Among 27 children who remained in public-assistance households throughout fiscal 2024, only 18 (66.7%) received the second dose of the measles-rubella vaccine; coverage remained approximately 60% during 2021-2023...These findings highlight the need for life stage-specific health promotion for children and younger recipients. Toyonaka City is currently planning targeted interventions based on these results."

Journal • Cervical Cancer • Dental Disorders • Genetic Disorders • Infectious Disease • Measles • Obesity • Oncology • Rubella • Solid Tumor

Conference Report on the 2025 Annual Review of the Essential Programme on Immunization in DR Congo: Dealing with Complexity. (PubMed, Vaccines (Basel)) - "Learning from the implementation of the 2025 AOP, the EPI stakeholders adopted a set of priority actions for the immunization programme in 2026."

Journal • Infectious Disease • Malaria • Measles • Rubella

ASSOCIATION BETWEEN IMMUNOLOGICAL STIMULI AND RELAPSE OF NEPHROTIC SYNDROME IN CHILDREN: A MULTICENTER PROSPECTIVE COHORT STUDY (ISN-WCN 2026) - "The breakdown of vaccinations was as follows: influenza vaccine, 21 times; Japanese encephalitis vaccine, 3 times; varicella vaccine, 3 times; mumps vaccine, 3 times; measles–rubella vaccine, 1 time; Coronavirus disease 2019 vaccine, 1 time; and diphtheria–tetanus toxoid vaccine, 1 time.As compared with the pre-stimuli period, the relapse rate of NS during the period between 0 to + 7 was significantly higher across all 126 stimuli (0.02 vs. 0.09 relapses per person-month, p = 0.01) and 92 episodes of fever ≥38°C (0.025 vs. 0.11 relapses per person-month, p = 0.01). Upon evaluation of the pre-vaccination period following the 33 vaccination events and the period between 0 to + 7, there was no significant difference in the relapse rate of NS (0.014 vs. 0.03 relapses per person-month, p = 0.61).When stratified by the timing of immunological stimuli, the proportion of patients who experienced a relapse of NS within 7 days following any immunological stimulus or an..."

Clinical • CNS Disorders • Glomerulonephritis • Infectious Disease • Influenza • Measles • Mumps • Nephrology • Novel Coronavirus Disease • Renal Disease • Respiratory Diseases • Rubella • Tetanus • Varicella Zoster

SHIELD: Strengthening HPV Immunization Through EPI Leveraged Delivery (clinicaltrials.gov) - P2 | N=115 | Not yet recruiting | Sponsor: International Vaccine Institute

New P2 trial • Oncology

Mumps Virus: Replication, Immune Response, and the Changing Landscape of Vaccine Effectiveness. (PubMed, Pathogens) - "The mumps vaccine, now included in combination with measles and rubella vaccines (MMR), was first made available in the 1960s...We review current epidemiological data, highlighting shifts in MuV transmission and genotype distribution, and discuss the need for updated or genotype-matched vaccines. By connecting molecular virology with real-world trends in disease spread and vaccine performance, this review aims to support ongoing efforts to strengthen mumps control strategies and inform the development of next-generation vaccines."

Journal • Review • CNS Disorders • Infectious Disease • Measles • Mumps • Otorhinolaryngology • Rubella

Investigation of a measles outbreak in Brondong subdistrict, Lamongan district, Indonesia, 2023. (PubMed, Western Pac Surveill Response J) - "The measles outbreak was attributed to a decline in immunization coverage, particularly for the second dose of the measles-rubella vaccine. This decrease was driven by multiple factors, including the impact of the COVID-19 pandemic, misconceptions related to religious beliefs, and the long interval between the first and second vaccine doses, which contributed to the patients who were lost to follow-up. Collectively, these factors increased the vulnerability of children to measles infection."

Journal • Retrospective data • Infectious Disease • Measles • Novel Coronavirus Disease • Rubella

Low-dose yellow fever vaccination in infants: a randomised, double-blind, non-inferiority trial. (PubMed, Lancet) - P4 | "Compared with the standard yellow fever vaccine dose, a dose of 500 IU did not meet the non-inferiority criterion, suggesting that minimum dose requirements in adults are not generalisable to infants. Therefore, standard yellow fever doses should be used for infants in the routine WHO Expanded Programme on Immunization."

Head-to-Head • Journal • Infectious Disease • Measles • Rubella

Hybrid microneedle patch for administration of measles and rubella vaccine with an on-patient medical record. (PubMed, J Control Release) - "Immunogenicity studies in cotton rats confirmed that neutralizing antibody titers were similar after measles vaccination by hybrid MNPs (containing NIR particles), conventional MNPs (without NIR particles) and subcutaneous injection. These findings suggest that hybrid MNPs enable co-administration of vaccines and NIR particles for OPMR or co-delivery of other materials requiring sequestration."

Journal • Infectious Disease • Measles • Rubella

The Effects of Iron Treatment on Malaria and Measles Vaccine Response in Kenyan Infants With Iron Deficiency (clinicaltrials.gov) - P=N/A | N=324 | Not yet recruiting | Sponsor: Nicole Stoffel | Trial completion date: Dec 2027 ➔ Apr 2028 | Initiation date: Jul 2025 ➔ Jan 2026 | Trial primary completion date: Sep 2027 ➔ Dec 2027

Trial completion date • Trial initiation date • Trial primary completion date • Hematological Disorders • Infectious Disease • Malaria • Measles

A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants (clinicaltrials.gov) - P2 | N=200 | Completed | Sponsor: GlaxoSmithKline | Active, not recruiting ➔ Completed

Trial completion

A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants (clinicaltrials.gov) - P1 | N=551 | Completed | Sponsor: GlaxoSmithKline | Active, not recruiting ➔ Completed

Trial completion

Safety and non-inferiority of multidose and single-dose vial formulations of EuTCV Vi-CRM197 versus Typbar TCV in healthy participants in Kenya and Senegal: a multicentre, observer-blind, randomised, phase 3 study. (PubMed, Lancet Glob Health) - "These data show that EuTCV Vi-CRM197 is immunologically non-inferior to Typbar TCV in infants 28 days after vaccination and that the overall safety and reactogenicity profiles in healthy infants, children, and adults studied in Kenya and Senegal were similar to Typbar TCV. These data support WHO prequalification."

Clinical • Head-to-Head • Journal • P3 data • Infectious Disease • Measles • Rubella

Immunogenicity and Safety Results of a Randomized, Three-Arm, Phase IV Clinical Trial of Concomitant Administration of Typhoid Vi Conjugate Vaccine with Measles and Rubella Vaccine in Healthy Infants. (PubMed, Viruses) - "Most adverse events were mild, and only one serious adverse event was reported. These findings support the co-administration of TCV and MR vaccine as a safe and effective strategy."

Clinical • Journal • P4 data • Infectious Disease • Measles • Rubella

A post-marketing safety surveillance study on vaccines in Chongqing, China from 2006 to 2021: Using a nationwide spontaneous reporting database with multiple data mining methods. (PubMed, Hum Vaccin Immunother) - "Allergic reactions were the most prevalent, with 2,743 cases (88.2% of the RAR), and the Measles-Rubella Vaccine (MR) had the highest IR of allergic reactions, reaching 267.1 cases per 100,000 doses administered...The overall safety of vaccines in Chongqing is satisfactory. Vaccine manufacturers should optimize the production process to enhance vaccine tolerability."

Journal • P4 data • Allergy • Cardiovascular • Infectious Disease • Measles • Rubella

High measles and rubella vaccine coverage and seroprevalence among Zambian children participating in a measles and rubella supplementary immunization activity. (PubMed, PLOS Glob Public Health) - "Although children vaccinated during this SIA were highly likely to have previously received routine vaccinations, the SIA reached a considerable number of susceptible children. Monitoring SIA effectiveness and efficiency through standardized metrics and formats is critical for impactful vaccine delivery strategies."

Journal • Infectious Disease • Measles • Rubella

A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants (clinicaltrials.gov) - P2 | N=200 | Active, not recruiting | Sponsor: GlaxoSmithKline | Recruiting ➔ Active, not recruiting

Enrollment closed

Infant Malaria Vaccine Schedule Optimization (clinicaltrials.gov) - P2 | N=1200 | Recruiting | Sponsor: PATH | Trial completion date: Nov 2027 ➔ Mar 2028 | Trial primary completion date: Nov 2027 ➔ Mar 2028

Trial completion date • Trial primary completion date • Infectious Disease • Malaria